BioCardia, Inc. Operating Lease, Payments
BioCardia, Inc. (BCDA) reported Operating Lease, Payments of $128.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-12
- BioCardia, Inc. operating lease, payments for the quarter ending 2026-06-30 was $128.00K, a 3.23% increase year-over-year.
- BioCardia, Inc. operating lease, payments for the quarter ending 2026-03-31 was $128.00K, a 2.40% increase year-over-year.
- BioCardia, Inc. operating lease, payments for the quarter ending 2025-12-31 was $49.00K.
- BioCardia, Inc. operating lease, payments for the quarter ending 2025-09-30 was $125.00K, a 2.46% increase year-over-year.
- BioCardia, Inc. operating lease, payments for fiscal 2025 was $423.00K, a 16.21% increase from fiscal 2024.
- BioCardia, Inc. operating lease, payments for fiscal 2024 was $364.00K, a 15.56% increase from fiscal 2023.
- BioCardia, Inc. operating lease, payments for fiscal 2023 was $315.00K, a 32.91% increase from fiscal 2022.
- BioCardia, Inc. operating lease, payments for fiscal 2022 was $237.00K, a 65.45% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $128.00K 10-Q · filed 2026-08-12 | $256.00K 10-Q · filed 2026-08-12 | $305.00K derived: sum of 3 quarters · filed 2026-08-12 | $430.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $128.00K 10-Q · filed 2026-05-15 | $177.00K derived: sum of 2 quarters · filed 2026-05-15 | $302.00K derived: sum of 3 quarters · filed 2026-05-15 | $426.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $174.00K derived: sum of 2 quarters · filed 2026-03-24 | $298.00K derived: sum of 3 quarters · filed 2026-08-12 | $423.00K 10-K · filed 2026-03-24 | ||
| 2025-09-30 | $125.00K 10-Q · filed 2025-11-12 | $249.00K derived: sum of 2 quarters · filed 2026-08-12 | $374.00K 10-Q · filed 2025-11-12 | $374.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $124.00K 10-Q · filed 2026-08-12 | $249.00K 10-Q · filed 2026-08-12 | $249.00K derived: sum of 3 quarters · filed 2026-08-12 | $371.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $125.00K 10-Q · filed 2026-05-15 | $125.00K derived: sum of 2 quarters · filed 2026-05-15 | $247.00K derived: sum of 3 quarters · filed 2026-05-15 | $368.00K derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $122.00K derived: sum of 2 quarters · filed 2026-03-24 | $243.00K derived: sum of 3 quarters · filed 2026-03-24 | $364.00K 10-K · filed 2026-03-24 | $365.00K 10-K · filed 2025-03-26 | |
| 2024-09-30 | $122.00K 10-Q · filed 2025-11-12 | $243.00K derived: sum of 2 quarters · filed 2025-11-12 | $364.00K 10-Q · filed 2025-11-12 | $326.00K derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $121.00K 10-Q/A · filed 2025-10-29 | $242.00K 10-Q/A · filed 2025-10-29 | $204.00K derived: sum of 3 quarters · filed 2025-10-29 | $321.00K derived: sum of 4 quarters · filed 2025-10-29 | ||
| 2024-03-31 | $121.00K 10-Q · filed 2025-05-14 | $83.00K derived: sum of 2 quarters · filed 2025-05-14 | $200.00K derived: sum of 3 quarters · filed 2025-05-14 | $318.00K derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $79.00K derived: sum of 2 quarters · filed 2025-03-26 | $197.00K derived: sum of 3 quarters · filed 2025-03-26 | $315.00K 10-K · filed 2025-03-26 | ||
| 2023-09-30 | $117.00K 10-Q · filed 2024-11-13 | $235.00K derived: sum of 2 quarters · filed 2024-11-13 | $353.00K 10-Q · filed 2024-11-13 | $303.00K derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $118.00K 10-Q · filed 2024-08-13 | $236.00K 10-Q · filed 2024-08-13 | $186.00K derived: sum of 3 quarters · filed 2024-08-13 | $300.00K derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $118.00K 10-Q · filed 2024-05-14 | $68.00K derived: sum of 2 quarters · filed 2024-05-14 | $182.00K derived: sum of 3 quarters · filed 2024-05-14 | $258.00K derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $64.00K derived: sum of 2 quarters · filed 2024-03-27 | $140.00K derived: sum of 3 quarters · filed 2024-03-27 | $237.00K 10-K · filed 2024-03-27 | ||
| 2022-09-30 | $114.00K 10-Q · filed 2023-11-08 | $190.00K derived: sum of 2 quarters · filed 2023-11-08 | $287.00K 10-Q · filed 2023-11-08 | $487.00K derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $76.00K 10-Q · filed 2023-08-09 | $173.00K 10-Q · filed 2023-08-09 | $373.00K derived: sum of 3 quarters · filed 2023-08-09 | $535.00K derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | $97.00K 10-Q · filed 2023-05-10 | $297.00K derived: sum of 2 quarters · filed 2023-05-10 | $459.00K derived: sum of 3 quarters · filed 2023-05-10 | $621.00K derived: sum of 4 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $362.00K derived: sum of 2 quarters · filed 2023-03-29 | $524.00K derived: sum of 3 quarters · filed 2023-03-29 | $686.00K 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $162.00K 10-Q · filed 2021-11-10 | $324.00K derived: sum of 2 quarters · filed 2022-08-10 | $486.00K 10-Q · filed 2021-11-10 | $967.00K derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $162.00K 10-Q · filed 2022-08-10 | $324.00K 10-Q · filed 2022-08-10 | $805.00K derived: sum of 3 quarters · filed 2022-11-09 | $963.00K derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $486.00K 10-Q · filed 2022-11-09 | $162.00K 10-Q · filed 2021-05-13 | $643.00K derived: sum of 2 quarters · filed 2022-11-09 | $801.00K derived: sum of 3 quarters · filed 2022-11-09 | $959.00K derived: sum of 4 quarters · filed 2022-11-09 | |
| 2020-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $315.00K derived: sum of 2 quarters · filed 2022-03-29 | $473.00K derived: sum of 3 quarters · filed 2022-03-29 | $630.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $158.00K 10-Q · filed 2021-11-10 | $316.00K derived: sum of 2 quarters · filed 2021-11-10 | $473.00K 10-Q · filed 2021-11-10 | $627.00K derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $158.00K 10-Q · filed 2021-08-12 | $315.00K 10-Q · filed 2021-08-12 | $469.00K derived: sum of 3 quarters · filed 2021-08-12 | $622.00K derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $158.00K 10-Q · filed 2021-05-13 | $311.00K derived: sum of 2 quarters · filed 2021-05-13 | $464.00K derived: sum of 3 quarters · filed 2021-05-13 | $617.00K derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $306.00K derived: sum of 2 quarters · filed 2021-03-30 | $459.00K derived: sum of 3 quarters · filed 2021-03-30 | $612.00K 10-K · filed 2021-03-30 | ||
| 2019-09-30 | $153.00K 10-Q · filed 2020-11-10 | $306.00K derived: sum of 2 quarters · filed 2020-11-10 | $459.00K 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | $153.00K 10-Q · filed 2020-08-13 | $306.00K 10-Q · filed 2020-08-13 | ||||
| 2019-03-31 | $153.00K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |